A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma

Kathy Miller, Patrick Loehrer, René Gonin, George Weber, Rafat Ansari, William Pletcher, John McClean, C. H. Spiridonidis, Joanne Mortimer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

From January 1992 through May 1993, 31 patients with adenocarcinoma of the pancreas or hepatocellular carcinoma were treated with weekly oral methotrexate (7.5 mg/M2 every 6 hours for 6 doses) and continuous oral AZT (200 mg four times daily). Patients were treated for a total of 6 months or until disease progression. The median age was 66 (range 44-79) and the median KPS was 80. No patient had received prior chemotherapy. Hematologic toxicity was severe with 50% of patients developing hemoglobins less than 8 gm/dl and 70% with granulocyte counts less than 1000 per mm3. One patient achieved a radiographic complete remission and 2 had stable disease. Two-thirds of patients progressed within 2 months of beginning therapy. The combination of methotrexate and AZT is an inactive regimen in pancreatic and hepatocellular carcinoma and is associated with considerable toxicity.

Original languageEnglish
Pages (from-to)207-212
Number of pages6
JournalInvestigational New Drugs
Volume14
Issue number2
StatePublished - 1996

Fingerprint

Zidovudine
Methotrexate
Pancreas
Hepatocellular Carcinoma
Adenocarcinoma
Granulocytes
Disease Progression
Hemoglobins
Drug Therapy

Keywords

  • Hepatocellular carcinoma
  • Methotrexate
  • Pancreatic carcinoma
  • Thymidine synthesis
  • Zidovudine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. / Miller, Kathy; Loehrer, Patrick; Gonin, René; Weber, George; Ansari, Rafat; Pletcher, William; McClean, John; Spiridonidis, C. H.; Mortimer, Joanne.

In: Investigational New Drugs, Vol. 14, No. 2, 1996, p. 207-212.

Research output: Contribution to journalArticle

Miller, K, Loehrer, P, Gonin, R, Weber, G, Ansari, R, Pletcher, W, McClean, J, Spiridonidis, CH & Mortimer, J 1996, 'A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma', Investigational New Drugs, vol. 14, no. 2, pp. 207-212.
Miller, Kathy ; Loehrer, Patrick ; Gonin, René ; Weber, George ; Ansari, Rafat ; Pletcher, William ; McClean, John ; Spiridonidis, C. H. ; Mortimer, Joanne. / A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. In: Investigational New Drugs. 1996 ; Vol. 14, No. 2. pp. 207-212.
@article{51005402ceb3424aafe8b1c6b2ae65ea,
title = "A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma",
abstract = "From January 1992 through May 1993, 31 patients with adenocarcinoma of the pancreas or hepatocellular carcinoma were treated with weekly oral methotrexate (7.5 mg/M2 every 6 hours for 6 doses) and continuous oral AZT (200 mg four times daily). Patients were treated for a total of 6 months or until disease progression. The median age was 66 (range 44-79) and the median KPS was 80. No patient had received prior chemotherapy. Hematologic toxicity was severe with 50{\%} of patients developing hemoglobins less than 8 gm/dl and 70{\%} with granulocyte counts less than 1000 per mm3. One patient achieved a radiographic complete remission and 2 had stable disease. Two-thirds of patients progressed within 2 months of beginning therapy. The combination of methotrexate and AZT is an inactive regimen in pancreatic and hepatocellular carcinoma and is associated with considerable toxicity.",
keywords = "Hepatocellular carcinoma, Methotrexate, Pancreatic carcinoma, Thymidine synthesis, Zidovudine",
author = "Kathy Miller and Patrick Loehrer and Ren{\'e} Gonin and George Weber and Rafat Ansari and William Pletcher and John McClean and Spiridonidis, {C. H.} and Joanne Mortimer",
year = "1996",
language = "English",
volume = "14",
pages = "207--212",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma

AU - Miller, Kathy

AU - Loehrer, Patrick

AU - Gonin, René

AU - Weber, George

AU - Ansari, Rafat

AU - Pletcher, William

AU - McClean, John

AU - Spiridonidis, C. H.

AU - Mortimer, Joanne

PY - 1996

Y1 - 1996

N2 - From January 1992 through May 1993, 31 patients with adenocarcinoma of the pancreas or hepatocellular carcinoma were treated with weekly oral methotrexate (7.5 mg/M2 every 6 hours for 6 doses) and continuous oral AZT (200 mg four times daily). Patients were treated for a total of 6 months or until disease progression. The median age was 66 (range 44-79) and the median KPS was 80. No patient had received prior chemotherapy. Hematologic toxicity was severe with 50% of patients developing hemoglobins less than 8 gm/dl and 70% with granulocyte counts less than 1000 per mm3. One patient achieved a radiographic complete remission and 2 had stable disease. Two-thirds of patients progressed within 2 months of beginning therapy. The combination of methotrexate and AZT is an inactive regimen in pancreatic and hepatocellular carcinoma and is associated with considerable toxicity.

AB - From January 1992 through May 1993, 31 patients with adenocarcinoma of the pancreas or hepatocellular carcinoma were treated with weekly oral methotrexate (7.5 mg/M2 every 6 hours for 6 doses) and continuous oral AZT (200 mg four times daily). Patients were treated for a total of 6 months or until disease progression. The median age was 66 (range 44-79) and the median KPS was 80. No patient had received prior chemotherapy. Hematologic toxicity was severe with 50% of patients developing hemoglobins less than 8 gm/dl and 70% with granulocyte counts less than 1000 per mm3. One patient achieved a radiographic complete remission and 2 had stable disease. Two-thirds of patients progressed within 2 months of beginning therapy. The combination of methotrexate and AZT is an inactive regimen in pancreatic and hepatocellular carcinoma and is associated with considerable toxicity.

KW - Hepatocellular carcinoma

KW - Methotrexate

KW - Pancreatic carcinoma

KW - Thymidine synthesis

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0029800623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029800623&partnerID=8YFLogxK

M3 - Article

C2 - 8913842

AN - SCOPUS:0029800623

VL - 14

SP - 207

EP - 212

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -